首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   20575篇
  免费   1411篇
  国内免费   77篇
耳鼻咽喉   144篇
儿科学   657篇
妇产科学   496篇
基础医学   3271篇
口腔科学   395篇
临床医学   2023篇
内科学   3992篇
皮肤病学   458篇
神经病学   2236篇
特种医学   513篇
外科学   1901篇
综合类   115篇
一般理论   27篇
预防医学   2155篇
眼科学   367篇
药学   1231篇
中国医学   38篇
肿瘤学   2044篇
  2023年   174篇
  2022年   126篇
  2021年   478篇
  2020年   416篇
  2019年   595篇
  2018年   676篇
  2017年   529篇
  2016年   602篇
  2015年   686篇
  2014年   836篇
  2013年   1178篇
  2012年   1675篇
  2011年   1658篇
  2010年   941篇
  2009年   834篇
  2008年   1478篇
  2007年   1411篇
  2006年   1283篇
  2005年   1238篇
  2004年   1086篇
  2003年   1110篇
  2002年   965篇
  2001年   132篇
  2000年   81篇
  1999年   108篇
  1998年   143篇
  1997年   118篇
  1996年   88篇
  1995年   121篇
  1994年   101篇
  1993年   100篇
  1992年   55篇
  1991年   66篇
  1990年   49篇
  1989年   46篇
  1988年   26篇
  1987年   43篇
  1986年   44篇
  1985年   53篇
  1984年   54篇
  1983年   45篇
  1982年   70篇
  1981年   51篇
  1980年   45篇
  1979年   37篇
  1978年   34篇
  1976年   30篇
  1975年   26篇
  1974年   33篇
  1973年   28篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
PurposeTRAPPC9 deficiency is an autosomal recessive disorder mainly associated with intellectual disability (ID), microcephaly, and obesity. Previously, TRAPPC9 deficiency has not been associated with biochemical abnormalities.MethodsExome sequencing was performed in 3 individuals with ID and dysmorphic features. N-Glycosylation analyses were performed in the patients’ blood samples to test for possible congenital disorder of glycosylation (CDG). TRAPPC9 gene, TRAPPC9 protein expression, and N-glycosylation markers were assessed in patient fibroblasts. Complementation with wild-type TRAPPC9 and immunofluorescence studies to assess TRAPPC9 expression and localization were performed. The metabolic consequences of TRAPPC9 deficiency were evaluated using tracer metabolomics.ResultsAll 3 patients carried biallelic missense variants in TRAPPC9 and presented with an N-glycosylation defect in blood, consistent with CDG type I. Extensive investigations in patient fibroblasts corroborated TRAPPC9 deficiency and an N-glycosylation defect. Tracer metabolomics revealed global metabolic changes with several affected glycosylation-related metabolites.ConclusionWe identified 3 TRAPPC9 deficient patients presenting with ID, dysmorphic features, and abnormal glycosylation. On the basis of our findings, we propose that TRAPPC9 deficiency could lead to a CDG (TRAPPC9-CDG). The finding of abnormal glycosylation in these patients is highly relevant for diagnosis, further elucidation of the pathophysiology, and management of the disease.  相似文献   
2.
3.
4.
5.
6.
Clinical Oral Investigations - This study evaluated the reproducibility of electronic color determination system evaluations of the marginal gingiva, which could be important for adhesive cervical...  相似文献   
7.
8.
9.
10.
Locally advanced rectal cancer has a rising global incidence. Over the last 4 decades, advances first in surgery and later in radiotherapy and chemoradiotherapy have improved outcomes, particularly with regard to local recurrence. Unfortunately, distant metastases remain a significant problem. In clinical trials of patients with stage II and III disease, distant relapse occurs in 25% to 30% of patients regardless of the treatment approach. Recent phase 3 trials have therefore focused on intensification of systemic therapy for localized disease, with an aim of reducing the distant relapse rate. Early results of trials of total neoadjuvant therapy with combination systemic therapy provided in the neoadjuvant setting are promising; for the first time, a significant improvement in the rate of distant relapse has been noted. Longer-term follow-up is eagerly awaited. On the other hand, trimodal therapy with chemotherapy, radiotherapy, and surgery is toxic. Several trials are currently assessing the feasibility of a watch-and-wait approach, omitting surgery in those with complete response to neoadjuvant treatment, in an attempt to reduce the burden of treatment on patients. The future for rectal cancer patients is likely to be highly personalized, with more intense approaches for high-risk patients and omission of unnecessary therapy for those whose disease responds well to initial treatment. Biomarkers such as circulating tumor DNA will help to more accurately stratify patients into risk groups. Improvements in survival and quality of life are expected as the results of ongoing research become available throughout the next decade.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号